Cefepime: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 27: | Line 27: | ||
'''| [[Cefepime directions for use|Directions For Use]]''' | '''| [[Cefepime directions for use|Directions For Use]]''' | ||
'''| [[Cefepime how supplied|How Supplied]]''' | '''| [[Cefepime how supplied|How Supplied]]''' | ||
'''| [[Cefepime labels and packages|Labels and Packages]]''' | '''| [[Cefepime labels and packages|Labels and Packages]]''' | ||
Revision as of 02:43, 26 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cefepime (INN) (IPA: Template:IPA) is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. Cefepime hydrochloride was first marketed in 1994 and is currently marketed under various trade names including Maxipime (Elan Pharma), Maxcef, Cepimax, Cepimex, and Axepim.
Category
Cephalosporin, Fourth-Generation
US Brand Names
MAXIPIME®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages